Rituximab immunotherapy: it’s getting personal

Mitch A. Phelps  THE OHIO STATE UNIVERSITY

In this issue of *Blood*, Tout and colleagues add another layer of personalization to rituximab therapy in patients with diffuse large B-cell lymphoma (DLBCL) by demonstrating the relationship between baseline total metabolic tumor volume (TMTV₀), rituximab exposure, and outcomes from therapy.¹

The foundation of precision medicine or personalized therapy is the idea that, for each patient, we can select the best available drug monotherapy or combination of therapies and the optimal dose regimen for this therapy to achieve maximum benefit for the patient. Rituximab was approved by the US Food and Drug Administration for use in DLBCL nearly 20 years ago. It was the first immunotherapy approved for specific use in cancer, and it quickly demonstrated a dramatic improvement in outcomes in patients with DLBCL when combined with chemotherapeutic agents.²³ Rituximab has since been approved for use in chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. It specifically targets CD20, which is expressed on normal B lymphocytes and on several types of malignant B cells. As an immunotherapy, rituximab is already a “personalized therapeutic” because patients whose tumors express higher levels of CD20 are expected to receive greater benefit from rituximab use. Not surprisingly, increased CD20 expression has been demonstrated to be correlated with improved survival in DLBCL.⁴ Furthermore, others had already demonstrated that higher rituximab exposure correlates with improved outcomes from therapy.⁵

But, it’s not that simple, of course. CD20 expression also influences the disposition of rituximab. This phenomenon is referred to as target-mediated drug disposition (TMDD), and it can occur when a substantial portion of a drug binds with high affinity and high specificity to a target.⁶

In cases where the drug binds its target irreversibly or is internalized and degraded after binding to its target, this binding can contribute directly to drug clearance. In other cases where the drug binds tightly but reversibly, receptor binding may serve as a distribution compartment, thus impacting the drug’s overall volume of distribution. TMDD can occur with small molecules,⁷ but it is more commonly observed with antibody therapeutics, including rituximab.⁸

In the current study by Tout and colleagues,¹⁹ ¹⁸F-fluorodeoxyglucose-positron emission tomography (PET)–computed tomography was used to measure TMTV₀ in 108 patients that were also assessed for rituximab pharmacokinetics. Because higher TMTV₀ (ie, higher tumor burden at baseline) would be expected to correlate with higher total CD20 expression, the investigators evaluated the influence of TMTV₀ on rituximab pharmacokinetics. Not surprisingly, they observed a strong correlation between TMTV₀ and rituximab disposition as demonstrated in the figure. Notably, although other groups have incorporated time-varying clearance to account for the target-mediated behavior of rituximab,⁵⁸ Tout and colleagues have attributed this behavior to changes in the volume of distribution. In either case, the higher the quantity of receptor present, the greater the influence on drug disposition.

In addition to progression-free and overall survival, PET imaging after 4 cycles of either R-CHOP-14 (rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone) or R-ACVBP-14 (rituximab, doxorubicin, cyclophosphamide, vincristine, bleomycin, and prednisone) was also available to provide a binary assessment of the complete metabolic response to treatment in 97 of the 108 patients. Again, as expected, the investigators observed relationships between rituximab pharmacokinetics and outcomes (progression-free survival, overall survival, and metabolic response, as...
shown in Figure 2C-F of Tout et al). A separate group recently reported metabolic tumor volume was associated with outcomes in DLBCL patients with bone marrow involvement. The additional contribution made in this current report by Tout and colleagues is that high TMTV₀, which correlates with lower favorable outcomes in patients receiving the standard 375 mg/m² dose of rituximab, also correlates with relatively low rituximab exposures. This same group had previously linked rituximab pharmacokinetics, tumor burden, and outcomes in a mouse model of lymphoma, but the current report is the first to provide a clinical data set demonstrating the link between all 3 of these variables.

Importantly, standard dosing in DLBCL with rituximab has remained at 375 mg/m² since early in its clinical development. Tout and colleagues have also constructed a nomogram based on their data, which provides a rational scheme for increasing the rituximab dose in patients receiving the standard 375 mg/m² dose of rituximab, also correlates with relatively low rituximab exposures. This same group had previously linked rituximab pharmacokinetics, tumor burden, and outcomes in a mouse model of lymphoma, but the current report is the first to provide a clinical data set demonstrating the link between all 3 of these variables.

There are many other immunotherapies that have been approved or are in development, and these target CD20 plus a variety of other antigens. Given that the basic behavior of these therapies will be similar to rituximab (ie, high-affinity and high-specificity binding to a single cancer-associated antigen), we can expect that similar relationships between target expression, pharmacokinetic exposure of these antibodies, and outcomes from therapy may exist, thus indicating that personalized dosing strategies may be feasible in diseases where target expression and/or tumor burden can be quantified. A recent review by Ku, Chong, and Hawkes nicely summarizes immunotherapies more recently approved or in development for B-cell malignancies, and they also point out that dosing regimens could be more optimally tuned for individuals. Although the proposed dosing nomogram for rituximab presented by Tout and colleagues must be further tested and validated, future personalized dosing regimen designs for other existing and new antibody therapies could benefit from the lessons learned with rituximab and the approaches taken by this group.

Conflict-of-interest disclosure: The author declares no competing financial interests.

**IMMUNOBIOLOGY**

Comment on Valgardsdottir et al, page 2636

**Neutrophils: positive or negative?**

Ronald P. Taylor  UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE

In this issue of *Blood*, Valgardsdottir et al demonstrate that human neutrophils do not kill chronic lymphocytic leukemia (CLL) B cells opsonized with the CD20 monoclonal antibody (mAb) rituximab (RTX) or obinutuzumab (OBBZ); instead, the neutrophils remove both CD20 and bound mAbs from B cells by trogocytosis. The CD20 mAb RTX was approved 20 years ago for treatment of relapsed or refractory, low-grade or follicular, B-cell non-Hodgkin lymphoma, and since that time, several next-generation CD20 mAbs have been approved or are under development for a variety of B-cell–associated malignancies. Although therapies that include CD20 mAbs (usually in combination with chemotherapy) have proven to be effective, in almost all cases they are not curative. In fact, often patients’ tumors become refractory to additional CD20 therapy, and in several instances, this has been attributed to loss of CD20 from targeted B cells. Therefore, there is a real need to enhance the potency of CD20 mAbs based on clearly delineating their mechanisms of action and the reasons for decreases in their efficacy. These issues have been the subject of intense investigations and some controversy. The report by Valgardsdottir et al clarifies the role of neutrophils in CD20 immunotherapy.

There is now consensus that CD20 mAbs must make use of immune effector functions to eliminate targeted B cells. mAb-opsonized B cells are subject to killing by cells that express Fcγ receptors (FcγRs), which allows these effector cells to engage the immune complexes composed of mAb immunoglobulin G molecules chelated to CD20 on targeted B cells. This initiates activating and signaling cascades specific to effector cells. Natural killer (NK) cells eliminate B cells by antibody-dependent cell-mediated cytotoxicity (ADCC); the B cells are directly lysed and killed as a result of NK-cell secretion of granzymes and perforin into the B cells. In addition, opsonized B cells are subject to phagocytosis and elimination by macrophages. Complement can mediate clearance and direct killing of mAb-opsonized cells, but in the present context, this mechanism is not relevant to the work of Valgardsdottir et al. FcγR-mediated trogocytosis is a reaction in which effector cells that are capable of killing CD20 mAb-opsonized cells instead form an immunological synapse with opsonized cells based on chelation of B-cell–bound immune complexes by FcγRs on effector cells. After formation of the synapse, the B-cell–bound CD20 mAbs,
Rituximab immunotherapy: it's getting personal

Mitch A. Phelps